Annexon Inc., a biopharmaceutical company listed on Nasdaq, announced on May 16, 2025, the approval of equity awards under the 2022 Employment Inducement Award Plan for two new non-executive employees. The inducement grants, approved on May 14, 2025, allow these employees options to purchase a total of 214,000 shares of Annexon common stock. These options have a ten-year term with an exercise price of $1.81 per share, aligning with the closing price on the grant date. The vesting schedule is structured over four years, with 25% of the shares vesting after the first year and the remaining shares vesting monthly thereafter, contingent upon continued service.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.